Microwave transurethral applicator with helix-loaded-dipole-antenna (HLDA) for prostate treatment.

Three designs of transurethral applicators have been analysed to find the one that is best able to selectively heat the desired volume of prostate. A helix-loaded-dipole-antenna (HLDA) inserted into a Foley type catheter was found to be the most promising design. A change in the heat deposition pattern of the antenna depending on prostate size is possible by moving the position of the antenna within a Foley catheter. A number of prototypes of HLDA were manufactured and tested to optimize their design. These tests were performed in solid and liquid phantoms and in laboratory animals. Intra-operative measurements of intra-prostatic temperature distribution were also performed. A comparison of the HLDA with other commercially available transurethral applicators and the published data showed that the present design has a higher linear homogeneity coefficient and a better heat deposition in the prostate.

Localized current field hyperthermia in carcinoma of the cervix: 3-D computer simulation of SAR distribution.

Software was developed for the 3D simulation of SAR distribution for a 500 kHz localized current field hyperthermia system to be used in patients with carcinoma of the cervix. This hyperthermia system was specifically designed for use with a modified Fletcher-Suit intracavitary applicator. It consists of software modules for data input, tetrahedral grid generation and a numerical calculation of SAR distribution using an adaptive, multilevel finite element code. The AVS (Advanced Visual System, Inc.) system was used for the visual presentation of the results. A quasi-static approach was employed for the determination of SAR distribution. Results of the performed numerical tests were presented and they showed an important, clinically relevant ability to obtain a selective power deposition. This selective power deposition depended on the applicator geometry, i.e. the distance between the components of a Fletcher-Suit applicator and their relative position and the use of different modes of excitation.

Cooled microwave transrectal applicator with adjustable directional beam for prostate treatment.

A new intracavitary applicator design for microwave hyperthermia, particularly for transrectal prostate treatment, is presented. It includes an exchangeable multisection antenna that enables us to create a required longitudinal heating pattern, a cooling system to shift the maximum temperature away from the surface and a microwave reflecting system embedded in the cooling system that allows one to shape the irradiation beam in a transverse direction. Independent control of the longitudinal and transverse irradiation patterns of the applicator along with the cooling system, enable precise heating of selected tissues. Results of SAR measurements, E-field measurements and steady state temperature distributions, in solid and liquid tissue-equivalent phantoms are presented. Clinical performance of this applicator was evaluated earlier in patients heated intraoperatively and in a phase I clinical study. The applicator was found capable of effectively heating a tissue volume extending radially 3-25 mm from the applicator surface, angularly defined by configuration of reflecting system and longitudinally determined by specific choice of the multisection antenna.

Transrectal hyperthermia as palliative treatment for advanced adenocarcinoma of prostate and studies of cell-mediated immunity.

During a fifteen-month period, 15 patients with progressive adenocarcinoma of the prostate (CaP) were treated with transrectal microwave hyperthermia (TRHT). There were 5 Stage T4 and 11 Stage T3 patients including 6 patients with skeletal metastases. Nine of the patients had severe and 6 had moderately severe signs and symptoms of CaP. TRHT was given six times at 2,450 MHz with temperature controlled at 43.5 degrees for thirty minutes. Cell-mediated immunity tests were performed before TRHT and at two, four, and six months post-therapy. The results of these tests were compared with those of 15 patients with benign prostatic hyperplasia (BPH) treated with the same TRHT and with 30 untreated normal volunteers. TRHT was well tolerated with mild acute toxicity noted in 3 patients (20%). Of the 15 patients treated, 2 (13%) showed scintigraphic evidence of regression of bone metastases. Five patients survived more than five years since treatment, and in 3 patients there was no evidence of CaP. A decrease of marked or moderate degree in signs and symptoms of CaP was noted in 8 patients (53%). The results of cell-mediated immunity tests were of interest. The 15 CaP patients prior to TRHT had lower OKT4/OKT8 ratio, lower PHA transformation index, and lower Con-A induced T-cell suppressor activity as compared with the 15 BPH patients and 30 healthy volunteers, who had normal immune parameters (p < 0.01). Following TRHT there was a significant increase in the monitored immune parameters noted in the 15 CaP patients (p < 0.01). This immune stimulation peaked at two months and gradually decreased to near pretreatment levels at six months. In the 15 BPH patients post-TRHT changes in immune tests were less apparent. The results of this small study, if confirmed, could be of clinical importance in patients with advanced prostate cancer.

Temperature steering in prostate by simultaneous transurethral and transrectal hyperthermia.

Localized hyperthermia (HT) is presently under investigation as a treatment for benign prostatic hyperplasia and carcinoma of the prostate (CaP). One popular approach employs a transrectal (TR) device, a directional microwave (MW) applicator inserted into the rectum and aimed at the prostate. Alternatively, in the transurethral (TU) technique, a symmetrically radiating MW antenna is placed directly within the prostatic urethra. Used individually, TR applicators are capable of effectively heating (> 42 degrees C) the prostate up to 2 cm from the rectum, whereas TU applicators selectively heat the periurethral tissue with effective radial penetration of about 0.6 cm. Neither technique is of much value in heating the anterior prostate. In general, the highest temperatures are produced in the tissue immediately adjacent to the surface of intracavitary microwave devices. However, when MW antennas are used in arrays, the resulting heating pattern can differ significantly from that of the individual antennas. Heating at depth can be selectively enhanced and "steered" by adjusting the phase relationship between the devices. Prostatic temperature profiles were measured in 6 patients treated with TR alone, TU alone, and simultaneous TR and TU heating. In the combined treatments different phase relationships between the antennas were applied. We found that a higher temperature could be produced in the center of the prostate than on the surface of either applicator for certain phase relationships, and that the temperature profiles could be changed by shifting phase. The results of these measurements are in agreement with those of a computer simulation. Based on the above data we feel the combined use of TU and TR hyperthermia may be justified in Phase I-II trials for patients with locally advanced CaP.

[Physical activity in acute cerebrovascular insufficiency]. / Aktywnosc ruchowa w ocenie ostrej niedomogi krazenia mózgowego.

It was noted that physical activity of 1052 patients hospitalized for the acute cerebral flow failure due to atheromatosis is an important indicator of the cerebral ischemia. Extension of ischemia evaluated on the basis of physical activity enables to foresee possible improvement and survival. Authors' own classification of physical activity may be helpful in the monitoring of cerebral flow failure therapy.

[Cerebral infarction--a general-medical problem]. / Zawal mózgu--problem ogólnolekarski.

A knowledge of events accompanying the acute coronary failure may help understanding the acute cerebral blood flow insufficiency leading to brain infarction. Cerebral blood flow should be treated as an integral part of the systemic blood circulation. It is of importance when the disease produces lesions to the vascular wall, and the brain looses its autoregulation functions. In such a situation every extracerebral disorders--even slight--may produce extensive lesions to nervous tissue. Therefore, the treatment of the acute cerebral circulation failure requires proper functioning of all factors which may affect hemodynamics and tissue metabolism. Duration of cerebral flow disorders plays an important role in the avoidance of unfavourable complications such as brain infarction. Therefore, every physician is obliged to undertake any possible actions preventing such complications.